Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, February 2007, p. 566-575, Vol. 51, No. 2
0066-4804/07/$08.00+0 doi:10.1128/AAC.00853-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism
Jeannette M. Whitcomb,
Wei Huang,
Signe Fransen,
Kay Limoli,
Jonathan Toma,
Terri Wrin,
Colombe Chappey,
Linda D. B. Kiss,
Ellen E. Paxinos, and
Christos J. Petropoulos*
Monogram Biosciences, Incorporated, South San Francisco, California 94080
Received 12 July 2006/
Returned for modification 14 August 2006/
Accepted 13 November 2006
Most human immunodeficiency virus type 1 (HIV-1) strains require either the CXCR4 or CCR5 chemokine receptor to efficiently enter cells. Blocking viral binding to these coreceptors is an attractive therapeutic target. Currently, several coreceptor antagonists are being evaluated in clinical trials that require characterization of coreceptor tropism for enrollment. In this report, we describe the development of an automated and accurate procedure for determining HIV-1 coreceptor tropism (Trofile) and its validation for routine laboratory testing. HIV-1 pseudoviruses are generated using full-length env genes derived from patient virus populations. Coreceptor tropism is determined by measuring the abilities of these pseudovirus populations to efficiently infect CD4+/U87 cells expressing either the CXCR4 or CCR5 coreceptor. Viruses exclusively and efficiently infecting CXCR4+/CD4+/U87 cells are designated X4-tropic. Conversely, viruses exclusively and efficiently infecting CCR5+/CD4+/U87 cells are designated R5-tropic. Viruses capable of infecting both CXCR4+/CD4+/U87 and CCR5+/CD4+/U87 cells are designated dual/mixed-tropic. Assay accuracy and reproducibility were established by evaluating the tropisms of well-characterized viruses and the variability among replicate results from samples tested repeatedly. The viral subtype, hepatitis B virus or hepatitis C virus coinfection, and the plasma viral load did not affect assay performance. Minority subpopulations with alternate tropisms were reliably detected when present at 5 to 10%. The plasma viral load above which samples can be amplified efficiently in the Trofile assay is 1,000 copies per ml of plasma. Trofile has been automated for high-throughput use; it can be used to identify patients most likely to benefit from treatment regimens that include a coreceptor inhibitor and to monitor patients on treatment for the emergence of resistant virus populations that switch coreceptor tropism.
* Corresponding author. Mailing address: Monogram Biosciences, Inc., 345 Oyster Point Boulevard, South San Francisco, CA 94080. Phone: (650) 866-7439. Fax: (650) 624-4132. E-mail:
cpetropoulos{at}monogrambio.com.
Published ahead of print on 20 November 2006.
Antimicrobial Agents and Chemotherapy, February 2007, p. 566-575, Vol. 51, No. 2
0066-4804/07/$08.00+0 doi:10.1128/AAC.00853-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Ogert, R. A., Ba, L., Hou, Y., Buontempo, C., Qiu, P., Duca, J., Murgolo, N., Buontempo, P., Ralston, R., Howe, J. A.
(2009). Structure-Function Analysis of Human Immunodeficiency Virus Type 1 gp120 Amino Acid Mutations Associated with Resistance to the CCR5 Coreceptor Antagonist Vicriviroc. J. Virol.
83: 12151-12163
[Abstract]
[Full Text]
-
Coakley, E., Reeves, J. D., Huang, W., Mangas-Ruiz, M., Maurer, I., Harskamp, A. M., Gupta, S., Lie, Y., Petropoulos, C. J., Schuitemaker, H., van 't Wout, A. B.
(2009). Comparison of Human Immunodeficiency Virus Type 1 Tropism Profiles in Clinical Samples by the Trofile and MT-2 Assays. Antimicrob. Agents Chemother.
53: 4686-4693
[Abstract]
[Full Text]
-
Johnston, Samantha. H., Lobritz, M. A., Nguyen, S., Lassen, K., Delair, S., Posta, F., Bryson, Y. J., Arts, E. J., Chou, T., Lee, B.
(2009). A Quantitative Affinity-Profiling System That Reveals Distinct CD4/CCR5 Usage Patterns among Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Strains. J. Virol.
83: 11016-11026
[Abstract]
[Full Text]
-
Hosoya, N., Su, Z., Wilkin, T., Gulick, R. M., Flexner, C., Hughes, M. D., Skolnik, P. R., Giguel, F., Greaves, W. L., Coakley, E., Kuritzkes, D. R.
(2009). Assessing Human Immunodeficiency Virus Type 1 Tropism: Comparison of Assays Using Replication-Competent Virus versus Plasma-Derived Pseudotyped Virions. J. Clin. Microbiol.
47: 2604-2606
[Abstract]
[Full Text]
-
O'Rourke, S. M., Schweighardt, B., Scott, W. G., Wrin, T., Fonseca, D. P. A. J., Sinangil, F., Berman, P. W.
(2009). Novel Ring Structure in the gp41 Trimer of Human Immunodeficiency Virus Type 1 That Modulates Sensitivity and Resistance to Broadly Neutralizing Antibodies. J. Virol.
83: 7728-7738
[Abstract]
[Full Text]
-
Frange, P., Galimand, J., Goujard, C., Deveau, C., Ghosn, J., Rouzioux, C., Meyer, L., Chaix, M.-L.
(2009). High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother
64: 135-141
[Abstract]
[Full Text]
-
Vandekerckhove, L., Verhofstede, C., Vogelaers, D.
(2009). Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients. J Antimicrob Chemother
63: 1087-1096
[Abstract]
[Full Text]
-
Poveda, E., Seclen, E., Gonzalez, M. d. M., Garcia, F., Chueca, N., Aguilera, A., Rodriguez, J. J., Gonzalez-Lahoz, J., Soriano, V.
(2009). Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother
63: 1006-1010
[Abstract]
[Full Text]
-
Yost, R., Pasquale, T. R., Sahloff, E. G.
(2009). Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection. Am J Health Syst Pharm
66: 715-726
[Abstract]
[Full Text]
-
Demarest, J. F., Amrine-Madsen, H., Irlbeck, D. M., Kitrinos, K. M., on behalf of the CCR102881 Clinical Study Team,
(2009). Virologic Failure in First-Line Human Immunodeficiency Virus Therapy with a CCR5 Entry Inhibitor, Aplaviroc, plus a Fixed-Dose Combination of Lamivudine-Zidovudine: Nucleoside Reverse Transcriptase Inhibitor Resistance Regardless of Envelope Tropism. Antimicrob. Agents Chemother.
53: 1116-1123
[Abstract]
[Full Text]
-
Kitrinos, K. M., Amrine-Madsen, H., Irlbeck, D. M., Word, J. M., Demarest, J. F., on behalf of the CCR100136 Study Team,
(2009). Virologic Failure in Therapy-Naive Subjects on Aplaviroc plus Lopinavir-Ritonavir: Detection of Aplaviroc Resistance Requires Clonal Analysis of Envelope. Antimicrob. Agents Chemother.
53: 1124-1131
[Abstract]
[Full Text]
-
Coetzer, M., Nedellec, R., Salkowitz, J., McLaughlin, S., Liu, Y., Heath, L., Mullins, J. I., Mosier, D. E.
(2008). Evolution of CCR5 Use before and during Coreceptor Switching. J. Virol.
82: 11758-11766
[Abstract]
[Full Text]
-
Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A., Wohlfeiler, M., Montana, J. B., McHale, M., Sullivan, J., Ridgway, C., Felstead, S., Dunne, M. W., van der Ryst, E., Mayer, H., the MOTIVATE Study Teams,
(2008). Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. NEJM
359: 1429-1441
[Abstract]
[Full Text]
-
Fatkenheuer, G., Nelson, M., Lazzarin, A., Konourina, I., Hoepelman, A. I.M., Lampiris, H., Hirschel, B., Tebas, P., Raffi, F., Trottier, B., Bellos, N., Saag, M., Cooper, D. A., Westby, M., Tawadrous, M., Sullivan, J. F., Ridgway, C., Dunne, M. W., Felstead, S., Mayer, H., van der Ryst, E., the MOTIVATE 1 and MOTIVATE 2 Study Teams,
(2008). Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection. NEJM
359: 1442-1455
[Abstract]
[Full Text]
-
Tsibris, A. M. N., Sagar, M., Gulick, R. M., Su, Z., Hughes, M., Greaves, W., Subramanian, M., Flexner, C., Giguel, F., Leopold, K. E., Coakley, E., Kuritzkes, D. R.
(2008). In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject. J. Virol.
82: 8210-8214
[Abstract]
[Full Text]
-
Fransen, S., Bridger, G., Whitcomb, J. M., Toma, J., Stawiski, E., Parkin, N., Petropoulos, C. J., Huang, W.
(2008). Suppression of Dualtropic Human Immunodeficiency Virus Type 1 by the CXCR4 Antagonist AMD3100 Is Associated with Efficiency of CXCR4 Use and Baseline Virus Composition. Antimicrob. Agents Chemother.
52: 2608-2615
[Abstract]
[Full Text]
-
Vandekerckhove, L., Verhofstede, C., Vogelaers, D.
(2008). Maraviroc: integration of a new antiretroviral drug class into clinical practice. J Antimicrob Chemother
61: 1187-1190
[Abstract]
[Full Text]
-
Huang, W., Toma, J., Fransen, S., Stawiski, E., Reeves, J. D., Whitcomb, J. M., Parkin, N., Petropoulos, C. J.
(2008). Coreceptor Tropism Can Be Influenced by Amino Acid Substitutions in the gp41 Transmembrane Subunit of Human Immunodeficiency Virus Type 1 Envelope Protein. J. Virol.
82: 5584-5593
[Abstract]
[Full Text]
-
Huang, W., Eshleman, S. H., Toma, J., Fransen, S., Stawiski, E., Paxinos, E. E., Whitcomb, J. M., Young, A. M., Donnell, D., Mmiro, F., Musoke, P., Guay, L. A., Jackson, J. B., Parkin, N. T., Petropoulos, C. J.
(2007). Coreceptor Tropism in Human Immunodeficiency Virus Type 1 Subtype D: High Prevalence of CXCR4 Tropism and Heterogeneous Composition of Viral Populations. J. Virol.
81: 7885-7893
[Abstract]
[Full Text]